AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vaccination Against Opportunistic Bacteria Early After Diagnosis Is Recommended.(Brief Article)
2001 APR 18 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Immunization against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) produces adequate antibodies in immunocompromised patients only early in their disease course, researchers have found.
Although the two vaccines are recommended for immunocompromised patients, researchers have questioned their usefulness in this group.
"We studied antibody responses to pneumococcal polysaccharide vaccine (Pneumovax-23) and to conjugated H. influenzae type b-vaccine (Act-Hib) in 25 patients with B-cell chronic lymphocytic leukemia (B-CLL)," reported A. Hartkamp and colleagues in The Netherlands.
Vaccination caused an increase from 38% to 50% in pneumococcal antibodies and from 35% to 48% in Hib antibodies, reported Hartkamp and team. The best responses were seen in patients with significantly less advanced stages of disease, higher gammaglobulin levels, total immunoglobulin (IgG) levels and IgG-subclasses 2 and 4 levels, and lower levels of soluble CD23, they noted ("Antibody responses to pneumococcal and ...
- Chronic Lymphocytic Leukemia (CLL) Patients Reach Five-Year Survival Milestone...
- Press release article from: PR Newswire May 3, 2005 700+ words
...traces of chronic lymphocytic leukemia (CLL) after receiving alemtuzumab had survived...detectable diseased cells in patients with CLL is associated with a prolonged overall and...monoclonal antibody approved for the treatment of CLL. "This study shows that it is possible...
- Neuro Bioscience Closes the Acquisition of CLL Pharma, S.A.
- Press release article from: Business Wire June 2, 2003 700+ words
...acquisition of the majority of outstanding shares of CLL Pharma S.A. French based CLL Pharma S.A. is engaged in the business of developing...the company's development. The acquisition of CLL enables Neuro Bioscience to leverage the CLL state...
- KineMed Reports Data Demonstrating New Insights into the Cellular Progression...
- Press release article from: PR Newswire March 1, 2005 700+ words
...progression of chronic lymphocytic leukemia (CLL). Data generated by KineMed and reported in this article show for the first time that CLL is not a static disease that results from...publication of this paper it was believed that CLL cells proliferate at a very slow rate and...
- Study reports success in treating refractory B-CLL, T-PLL.(chronic lymphocytic...
- Newspaper article from: Cancer Weekly January 14, 2003 700+ words
...refractory B-cell chronic lymphocytic leukemia (B-CLL) and T-prolymphocytic leukemia (T-PLL...in the treatment of refractory/relapsed B-CLL showing increased response rates among B-CLL patients. Findings also show alemtuzumab to be...
- Study reports success in treating refractory B-CLL, T-PLL.
- Newspaper article from: Immunotherapy Weekly January 15, 2003 700+ words
...refractory B-cell chronic lymphocytic leukemia (B-CLL) and T-prolymphocytic leukemia (T-PLL...in the treatment of refractory/relapsed B-CLL showing increased response rates among B-CLL patients. Findings also show alemtuzumab to be...
- Study Defines New Endpoint in the Treatment of CLL.
- Press release article from: PR Newswire December 8, 2003 700+ words
...patients with chronic lymphocytic leukemia (CLL). The overall survival for patients who...the blood and bone marrow of patients with CLL is a realistic goal," according to Peter...worthwhile target in poor risk patients with CLL." In the study a total of 91 relapsed...
- Compassionate Use Study Reports Successes in Treating Refractory B-CLL and...
- Press release article from: PR Newswire December 9, 2002 700+ words
...refractory B-cell chronic lymphocytic leukemia (B-CLL) and T-prolymphocytic leukemia (T-PLL...in the treatment of refractory/relapsed B-CLL showing increased response rates among B-CLL patients. Findings also show alemtuzumab to be...
- National Cancer Institute Study to Determine the Optimal Time for CLL Patients...
- Press release article from: PR Newswire December 4, 2007 700+ words
...patients with chronic lymphocytic leukemia (CLL) and is designed to test the hypothesis...us to understand the natural history of CLL with respect to early versus delayed progression...segregate patients within all stages of CLL. Studies show that CLL patients with mutations...
Source: HighBeam Research, Vaccination Against Opportunistic Bacteria Early After Diagnosis Is...